IN8BIO CEO granted 154,500 stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
IN8BIO, INC. CEO William Tai-Wei Ho received an employee stock option grant covering 154,500 shares of common stock at an exercise price of $1.58 per share. The option expires on May 9, 2036 and represents compensation, not an open-market purchase.
The award vests in four equal installments of 25% each on November 9, 2026, May 9, 2027, November 9, 2027, and May 9, 2028, contingent on the CEO continuing to provide service through each vesting date.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) | 154,500 | $0.00 | $0.00 |
Footnotes (1)
- F1. Twenty-five percent (25%) of the shares subject to the option shall vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, subject to the Reporting Person continuing to provide service through each such date.
Key Figures
Key Terms
Employee Stock Option financial
exercise price financial
vesting financial
Common Stock financial
Form 4 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did IN8BIO (INAB) disclose about CEO William Ho in this Form 4?
How many options did IN8BIO (INAB) grant to its CEO and at what price?
What is the vesting schedule for the IN8BIO (INAB) CEO’s new stock options?
How many stock options does the IN8BIO (INAB) CEO hold after this reported grant?
When do the newly granted IN8BIO (INAB) CEO options expire?
AI-generated analysis. How Rhea-AI works. Not financial advice.